Journal Logo


Congenital hypofibrinogenemia in pregnancy

a report of 11 cases

Cai, Hea; Liang, Meiyinga; Yang, Jingjinga; Zhang, Xiaohuib

Author Information
Blood Coagulation & Fibrinolysis: March 2018 - Volume 29 - Issue 2 - p 155-159
doi: 10.1097/MBC.0000000000000676
  • Open



Congenital hypofibrinogenemia, first reported in 1935 [1], is defined as plasmafibrinogen levels below 150 mg/dl [2]. The incidence of the disease is unknown as it is a hereditary bleeding disorder and often caused by heterozygosity of a fibrinogen (FIB) gene mutation [2]. Individuals with plasma FIB concentrations 50–150 mg/dl, considered as having moderate hypofibrinogenemia, are mainly asymptomatic and essentially experience posttraumatic hemorrhages [2,3]. Pregnancy with congenital hypofibrinogenemia is a rare but a high-risk condition. Currently, only a few reports are available on pregnancy associated with hypofibrinogenemia; since 1961, only 10 cases of this disorder during pregnancy have been described [4–11]. Owing to the rarity of the disease and the absences of randomized controlled studies, management of pregnancy with hypofibrinogenemia is challenging. Most clinicians care only a few patients, and hence, their experience is limited.

During the past 5 years, the center of diagnosis and treatment for the hematological systemic disorder associated with pregnancy, in Peking University People's Hospital, experienced 11 cases and 12 successful deliveries with hypofibrinogenemia. In the present article, we described these patients’ plasma levels of FIB throughout pregnancy and summarized the maternal and fetal outcomes.

Materials and methods

The present retrospective study recruited 11 cases of congenital hypofibrinogenemia in the unit of Peking University people's Hospital during a 5-year period (01/10/2011–30/09/2016). The demographic baseline data, clinical characteristics, laboratory test results, management during pregnancy, mode of delivery, obstetrical complications, as well as, neonatal weight and viability of newborns were collected from the electronic and article records of women with hypofibrinogenemia during pregnancy. The FIB levels and signs of bleeding in the newborns were assessed by telephonic interview 6 weeks after birth. The study was approved by the local Ethics Committee of Peking University people's Hospital. Informed consent was not required as it is a retrospective study. However, all women attending our center were requested to sign an informed consent to allow the usage of their data for scientific purposes and contact for follow-up.

The diagnosis of hypofibrinogenemia was based on a standard hemostasis assessment confirmed by hematologists. As described previously, women with plasma FIB concentration less than 150 mg/dl were enrolled in the study. All the patients had undergone liver function tests to exclude liver disease, as it was a common cause of acquired FIB abnormality.

For patients diagnosed with hypofibrinogenemia, Clauss FIB assays were performed at least once a month, before and after the treatment throughout pregnancy. The signs for bleeding disorders, placental abruption, and fetal growth were monitored during the gestation period. The timing and mode of delivery were decided based on the condition of maternal and fetal complications. We attempted to maintain the full-term pregnancy, if no complications were revealed.

The decision of whether or not to start FIB substitution was based on the patient's personal and family history. At our center, in all cases of pregnancies involving patients with low levels of FIB, hematologists trained in the care of patients with rare bleeding disorders would be contacted. The amount of FIB concentrate (Shanghai RAAS Blood products Co., Ltd, Shanghai, China) was administrated = [target fibrinogen levels (g/l) − measured fibrinogen level] × 0.043 × weight (kg). However, the dosage of the prophylaxis was adapted to the patient's clinical course.

Complications including bleeding in early gestations, premature delivery, fetal growth restriction, placental abruption, postpartum hemorrhage, and postpartum thrombosis were recorded. Postpartum hemorrhage was defined as more than 500-ml vaginal or 1000-ml cesarean blood loss, respectively.


Patient characteristics

We encountered 11 cases and 12 full-term deliveries with congenital hypofibrinogenemia in the last 5 years. Four patients were referred to our hospital during the third trimester because of low levels of FIB. The demographic characteristics of the study population are presented in Table 1. The mean age of the 11 patients was 27.1 ± 3.3 (22–32) years. One woman (case 4) was diagnosed with hypofibrinogenemia at the age of 21 following induced abortion with her first pregnancy. Case 6 was diagnosed with hypofibrinogenemia 2 years ago during preoperative coagulation tests for appendectomy. In other cases, hypofibrinogenemia was diagnosed by routine test in progestation and in early pregnancy, and none of them showed bleeding tendency during pregnancy. The results of the clotting study, including prothrombin time (PT), activated partial thromboplastin time, and platelet counts, were normal, with the exception of FIB levels. Their prepregnancy FIB levels were ranged from 48 to 111 mg/dl (Table 1). All patients were excluded for the disease caused by secondary FIB decrease, thereby rendering10 nulliparous cases and one parous case. Positive family histories of hypofibrinogenemia were recorded for 8/11 cases, whereas none of their families had any episodes of hemorrhage or thrombosis. One patient (case 8) was diagnosed with severe hypofibrinogenemia (FIB < 50 mg/dl), whereas the others presented a moderate disease (FIB 50–150 mg/dl).

Table 1
Table 1:
Summary of 11 cases with congenital hypofibrinogenemia

Maternal and fetal outcomes

The course of pregnancy was uneventful in the 12 deliveries. The mean gestational age was 39 (38–40) weeks. There were eight vaginal deliveries including one forceps delivery and four cesarean sections. The surgeries were obligatory owing to a scarred uterus, suspected fetal macrosomia, prolonged second stage of labor, and low placenta, respectively. Case 4 experienced a vaginal delivery. She was first presented in our clinic, before 2 years, during her second pregnancy. Clotting tests revealed the trough levels of hypofibrinogenemia as 48 mg/dl. She delivered at 40-week gestation by obstetric forceps because of the meconium-stained amniotic fluid (case 4-1). Then, in her third pregnancy, the plasma FIB level was approximately 48–66 mg/dl throughout the pregnancy; a healthy infant was delivered vaginally (case 4-2).

The birth weight and Apgar scores at 1-min postbirth were reported in all patients. The mean birth weight was 3349 (3000–3780) g. None of the newborns achieved an Apgar score of less than 10 at the first 1 min. A total of 5/12 newborns were diagnosed with low levels of FIB in the follow-up periods (Table 2); however, no bleeding complications were reported.

Table 2
Table 2:
Fibrinogen levels throughout the pregnancy and obstetric courses among patients with congenital hypofibrinogenemia (n = 11)

Fibrinogen levels throughout pregnancy

FIB levels were supervised closely and regularly during the entire duration of pregnancy. The mean FIB levels during the three trimesters of pregnancy were 75.7 ± 43.9 (25–148), 67.6 ± 33.7 (22–146), and 77.9 ± 29.2 (32–148) mg/dl, respectively (Table 1).

The trough and peak levels of plasma FIB throughout pregnancy are presented in Table 2. One patient (case 8) experienced severe hypofibrinogenemia (trough FIB level was 22 mg/dl). However, no vaginal bleeding was reported during the pregnancy and yet a good pregnancy outcome after FIB substitution was observed.

The plasma FIB levels by gestational age are summarized in Fig. 1. The mean concentrations of FIB were 75.7 ± 43.9 (25–148) mg/dl before 13 weeks of gestation, 67.3 ± 35.6 (28–140) mg/dl in 20 weeks, 66.8 ± 33.4 (35–142) mg/dl in 24 weeks, 68.9 ± 36.4 (22–146) mg/dl in 28 weeks, 76.5 ± 33.9 (32–140) mg/dl in 32 weeks, 76.9 ± 28.5 (48–142) mg/dl in 36 weeks, and 80.8 ± 29.2 (39–148) mg/dl in 38 weeks of gestation.

Fig. 1
Fig. 1:
The plasma fibrinogen levels by gestational age.

The mean plasma FIB levels before and after FIB substitutions were 82.4 ± 28.6 and 152.9 ± 42.1 mg/dl, respectively. In the postpartum period, the mean FIB concentrations were then decreased to 118.8 ± 57.0 mg/dl (Table 2).


All the patients were followed up in our high-risk pregnancy clinic unit during the duration of pregnancy. No signs of placental abruption or vaginal bleeding were observed during pregnancy. None of the patients suffered from preterm delivery, and the mean gestational age was 39 (38–40) weeks. Any signs of intrauterine growth restriction were not presented, and the average birth weight was 3349 (3000–3780) g. The postpartum courses were unremarkable with no significant hemorrhagic or thrombotic complications (Table 1).


In the present report, 11 pregnant women with congenital hypofibrinogenemia were asymptomatic during the gestation and were diagnosed by routine examination. After examining the obstetric courses, we found that their pregnancies were uneventful and no significant associated bleeding or thrombotic complications were exhibited. The levels of FIB did not decrease significantly as gestational stage progressed. By careful monitoring of the FIB levels and supportive therapy, we achieved 12 term deliveries with 12 healthy newborns.

Congenital hypofibrinogenemia is a rare condition. The previous studies showed that individuals with this disorder are usually asymptomatic as moderate FIB levels are sufficient to prevent spontaneous bleeding [3,12]. A retrospective study including 100 patients with FIB deficiencies indicated that the mean incidence of bleeding episodes was 0.5%, and hypofibrinogenemia with bleeding was nonspontaneous and induced by trauma or surgery [12]. Pregnancy and delivery are extremely high-risk situations; women with hypofibrinogenemia are more prone to bleeding. However, none of the patients in our study showed a bleeding tendency during pregnancy. Although the levels of FIB were 22–48 mg/dl in case 8, no bleeding incident was observed in the periods of gestation.

According to the results of the current study, the amounts of FIB in our patients remained relatively stable during pregnancy. In fact, normal pregnancy is a condition in which significant changes occur in the hemostatic system with an increased tendency to coagulation. The view of the literature revealed that normal pregnancy causes a maternal physiological hypercoagulable state, and FIB levels progressively increase throughout the pregnancy. The study by Liu et al.[13] on normal pregnant women demonstrated that the FIB levels increased significantly between weeks of 12 and 20, remained relatively stable between weeks of 21 and 27, started to significantly increase again between weeks of 28 and 35, and remained unchanged between weeks of 26 and 42. Their patients were healthy women, whereas women involved in ours were all with hypofibrinogenemia, which might explicate the FIB levels in our patients were not remarkably higher during the late gestational weeks as compared with early pregnancy. The increasing levels of FIB are considered to prepare for controlling bleeding quickly and effectively. Therefore, pregnant women with low FIB must be taken seriously.

FIB abnormalities have been implicated in many adverse pregnancy outcomes, mainly placental abruption, postpartum hemorrhage, and thrombosis [9]. FIB plays a fundamental role in maintaining the integrity of the placenta by supporting cytotrophoblast spreading for the development of fetal–maternal vascularization [6]. However, in this report, none of the women suffered from significant postpartum hemorrhage or placenta abruption events. This satisfying outcome may be associated with the FIB replacement therapy before delivery. An increased prevalence of placental abruption has been reported in women with hypofibrinogenemia who did not receive FIB replacement [6].

FIB substitution is speculated as the cornerstone to a successful outcome in pregnant women with congenital hypofibrinogenemia [14,15]. Current FIB replacement is administered in the forms of fresh frozen plasma (FFP), cryoprecipitate, or FIB concentrate. Almost all the cases in our report were administered FIB concentrate, and 7/12 deliveries were infused with additional FFP before delivery. Though FFP and cryoprecipitate are less expensive, they require administration of larger volumes, which is of concern in the peripartum period, as women in labor often receive other treatments (e.g., oxytocin) that predispose to fluid overload and edema. Finally, anaphylatoxins in FFP and cryoprecipitate could lead to severe allergic reactions [14]. Thus, with respect to the advantages, FIB concentrate seems to be the best choice.

To evaluate the amount of FIB to be administered, a consensus on the optimal peripartum management is absent. In an open-label prospective study, FIB concentrates leading to a median fibrinogenemia levels of 145 mg/dl were effective in 11 surgical procedures [16]. However, extrapolations from perioperative management to peripartum management may be controversial. Several experts suggest substitution with FIB to attempt a trough level more than 50 mg/dl during the first two trimesters and more than 100 mg/dl at the end of the pregnancy. At delivery, the target FIB levels should be above 200 mg/dl to decrease the risk of postpartum hemorrhage [17,18].

Thrombosis related to FIB substitution has been reported, and an evaluation of thrombotic risk factors should be assessed in pregnant women with FIB disorders [10,19,20]. Placenta abruption is also alleged as a thrombotic complication. One of the potential explanations for thrombotic tendency is that, in the absence of FIB, the antithrombin function of fibrin is impaired. Kaparou et al.[10] also suggested that the complication of thrombosis was associated with the coexistence of a structural defect in the FIB molecule. Thromboprophylaxis with low-molecular heparin is recommended by some studies due to the ability to monitor the PT [20]. However, the correlation between FIB replacement and the incidence of thrombosis is still difficult to establish. In a systematic review, Bornikova et al.[21] reported two patients with thrombotic complications temporally associated with FIB perfusion; nevertheless, the correlation was not found in the other four cases. As none of the women in the present report showed a personal history of previous thrombotic events and substitution of FIB was stopped in the postpartum period, heparin was not used for treatment. None of them had suffered from any episodes of thrombosis.

Pregnant women with these diseases have been reported previously, most of whom experienced an elective or emergency cesarean delivery. However, we reported seven cases with successful vaginal deliveries including a case delivering two infants. Furthermore, the reasons for surgical deliveries for the remaining four cases were not because of FIB disorders but rather obstetric indications such as stagnation. This phenomenon strongly suggested that pregnancy combined with hypofibrinogenemia could have successful vaginal deliveries under meticulous monitoring and supportive FIB replacement.


In summary, we postulate that specific treatment, other than close observation and monitoring, is not required if bleeding or thrombotic events were absent in the patient's personal or family history: an appropriate supervision of the coagulation function and focusing on the changes such as FIB and other indexes as necessary. Cesarean delivery is not the indication in women with abnormal FIB levels; on the contrary, vaginal delivery is more beneficial for this subtype.


We thank the participating pregnant women for their conscientious cooperation and the experts at the Division of Hematology for their assistance.

Contributors: H.C. drafted article. M.L. contributed to study concept. J.Y. undertook data collection. X.Z. contributed the revision of article.

Conflicts of interest

There are no conflicts of interest.


1. de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009; 35:356–366.
2. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39:585–595.
3. Casini A, de Moerloose P. Management of congenital quantitative fibrinogen disorders: a Delphi consensus. Haemophilia 2016; 22:898–905.
4. Pritchard JA. Chronic hypofibrinogenemia and frequent placental abruption. Report of a case. Obstet Gynecol 1961; 18:146–151.
5. Hahn L, Lundberg PA. Congenital hypofibrinogenaemia and recurrent abortion. Case report. Br J Obstet Gynaecol 1978; 85:790–793.
6. Ness PM, Budzynski AZ, Olexa SA, Rodvien R. Congenital hypofibrinogenemia and recurrent placental abruption. Obstet Gynecol 1983; 61:519–523.
7. Kitchens CS, Cruz AC, Kant JA. A unique 7p/12q chromosomal abnormality associated with recurrent abortion and hypofibrinogenemia. Blood 1978; 70:921–925.
8. Goodwin TM. Congenital hypofibrinogenemia in pregnancy. Obstet Gynecol Surv 1989; 44:157–161.
9. Frenkel E, Duksin C, Herman A, Sherman DJ. Congenital hypofibrinogenemia in pregnancy: report of two cases and review of the literature. Obstet Gynecol Surv 2004; 59:775–779.
10. Kaparou M, Danilatou V, Lydaki E, Stathoudakis G, Bolonaki I, Nikoloudi I, Foundouli K. Prophylactic administration of fibrinogen concentrate in a pregnant woman with congenital hypofibrinogenemia and a positive obstetric history of severe bleeding in previous cesarean section. Blood Coagul Fibrinolysis 2012; 23:566–568.
11. Teraoka Y, Miyoshi H, Oshima K, Urabe S, Tanaka N, Kudo Y. Prenatal and peripartum management of patients with hypofibrinogenemia resulted in two successful deliveries. Case Rep Obstet Gynecol 2017; 2017:9427359.
12. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4:1634–1637.
13. Liu J, Yuan E, Lee L. Gestational age-specific reference intervals for routine haemostatic assays during normal pregnancy. Clin Chim Acta 2012; 413:258–261.
14. Bevan DH. Cryoprecipitate: no longer the best therapeutic choice in congenital fibrinogen disorders? Thromb Res 2009; 124 (suppl 2):S12–S16.
15. Kreuz W, Meili E, Peter-Salonen K, Haertel S, Devay J, Krzensk U, Egbring R. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci 2005; 32:247–253.
16. Weiss G, Lison S, Glaser M, Herberger S, Johanning K, Strasser T, et al. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register. Blood Coagul Fibrinolysis 2011; 22:727–734.
17. Mensah PK, Oppenheimer C, Watson C, Pavord S. Congenital afibrinogenaemia in pregnancy. Haemophilia 2011; 17:167–168.
18. Kobayashi T, Kanayama N, Tokunaga N, Asahina T, Terao T. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 2000; 109:364–366.
19. Lebreton A, Casini A, Alhayek R, Kouteich KL, Neerman-Arbez M, de Moerloose P. Successful pregnancy under fibrinogen substitution in a woman with congenital afibrinogenaemia complicated by a postpartum venous thrombosis. Haemophilia 2015; 21:e108–e110.
20. Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost 2016; 42:366–374.
21. Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9:1687–1704.

complication; fibrinogen replacement; hypofibrinogenemia; pregnancy

Copyright © 2018 YEAR Wolters Kluwer Health, Inc. All rights reserved.